# Study of REM-422 in Patients With AML or Higher Risk MDS

> **NCT06297941** · PHASE1 · RECRUITING · sponsor: **Remix Therapeutics** · enrollment: 100 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Higher Risk Myelodysplastic Syndromes
- Acute Myeloid Leukemia
- Acute Myeloid Leukemia Refractory

## Interventions

- **DRUG:** REM-422

## Key facts

- **NCT ID:** NCT06297941
- **Lead sponsor:** Remix Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-26
- **Primary completion:** 2026-03-15
- **Final completion:** 2027-06-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297941, "Study of REM-422 in Patients With AML or Higher Risk MDS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06297941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*